Site Search

... delivery of precision cancer treatments. ACS CAN will advocate for robust and sustained federal funding annually for the National Institutes of Health and National Cancer Institute, to promote development of innovative cancer prevention, early detection, and treatment. Eliminate ... resources in their communities. ACS CAN will pursue federal and state policies nationwide that reduce cancer disparities through access to health insurance coverage, addressing financial toxicity through increasing care affordability, and reducing barriers that lead to more diverse enrollment in clinical trials. Deliver Best Care: Our health care system ...

OKLAHOMA CITY – Nov. 9, 2020 – Cancer patients and survivors continue to experience potentially serious health care delays during the pandemic, and tomorrow leadership across Oklahoma will shine a light on the disparities affecting Native Americans’ cancer ... (32%). WHO:                 Dr. Jessica W. Blanchard , the University of Oklahoma Tamela K. Cannady , Director of Preventative Health, Choctaw Nation Health Services Authority Dr. Mark P. Doescher , Stephenson Cancer Center Jacque Secondine Hensley , Director of American ...

... Moonshot goal a reality,” said Dr. Karen E. Knudsen, CEO of ACS and ACS CAN. “We were pleased to hear the President again call on lawmakers, health care providers, the cancer community at large and the American people to join together in this mission. By accelerating discovery, improving access ... with the administration outlining policy changes that would help bring the US closer to the President’s goal, including increasing access to health coverage through Medicaid expansion, increasing funding for cancer research at the NIH and NCI, appropriating additional funding for a new ...

... (ACS CAN) released new policy recommendations today to increase uptake of biomarker testing and advance the use of precision medicine in cancer care. The recommendations follow the release of new data that shows access is not keeping up with innovation when it comes to biomarker testing.  ... diagnostic testing necessary to utilize this promising treatment strategy.” A new report by ACS CAN and the LUNGevity Foundation found while health insurance coverage for biomarker testing has improved since the organizations’ last report in 2018, coverage is still failing to keep up ... remain. The review, which focused on breast, colorectal, lung and prostate cancers, found coverage is more prominent for single-gene tests, and health insurance companies are still slow to cover multi-gene panels.  Additionally, in an ACS CAN  survey of cancer patients and survivors ...